Is Edgewise Therapeutics (EWTX) Undervalued As EDG 7500 Moves Toward Phase 3?
Edgewise Therapeutics (EWTX) just cleared a key regulatory hurdle for EDG-7500, reporting a favorable End-of-Phase 2 meeting that set the foundation for its pivotal STRATUS-HCM Phase 3 trial starting in Q4 2026.
Investors have already moved the share price to US$45.93, with a 30 day share price return of 24.07% and a year to date share price gain of 93.39%. Total shareholder return of 101.89% over one year and roughly 7x over three years points to strong momentum building around Edgewise Therapeutics as the EDG-7500 program and recent earnings progress reshape perceived risk and potential reward.
Scan biopharma ideas riding similar clinical and earnings momentum to Edgewise Therapeutics with a curated set of 20 high quality undiscovered gems.
Bulls see Edgewise Therapeutics priced for real clinical and earnings power after EDG-7500 progress and a sharp rerating. Bears see froth. The numbers and current multiples now need to settle that argument.
Most Popular Narrative: 15% Undervalued
On the analyst consensus Narrative on Simply Wall St, Edgewise Therapeutics screens as undervalued, with a fair value of $54.00 against the last close at $45.93. This puts the current rally in the context of longer term earnings and revenue forecasts built into that view.
The analysts have a consensus price target of $54.0 for Edgewise Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you would need to believe that by 2029, revenues will be $135.6 million, earnings will come to $22.1 million, and it would be trading on a PE ratio of 352.9x, assuming you use a discount rate of 7.2%.
See why 1 investors see Edgewise Therapeutics as 15% undervalued.
Result: Fair Value of $54.00 (UNDERVALUED)
Still, the bullish Edgewise Therapeutics story can crack if EDG-7500 stumbles in later stage trials or if heavy R&D spending extends the period of losses.
Find out about the key risks to this Edgewise Therapeutics narrative.
Next Steps
Strong optimism runs through this Edgewise Therapeutics story, yet real risks sit alongside the potential rewards. Move quickly and review the full set of 4 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Edgewise Therapeutics?
Do not stop with Edgewise Therapeutics when a wider set of opportunities is only a few minutes of focused research away on the Simply Wall St screener.
- Target potential mispricings by scanning a focused set of 32 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying business strength.
- Prioritise capital protection by filtering for 31 resilient stocks with low risk scores that score well on stability, financial health, and lower historical volatility.
- Get ahead of the crowd by reviewing a curated 20 high quality undiscovered gems before wider market attention chases the same opportunities.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com